<DOC>
	<DOCNO>NCT01298934</DOCNO>
	<brief_summary>LBH589 oral drug target myelofibrosis cell bone marrow induces cell death allow expression certain suppress gene important regulating cell survival . Based laboratory study , hypothesis drug selectively kill stem cell responsible cause myelofibrosis result reduction spleen size ultimately restoration normal bone marrow function .</brief_summary>
	<brief_title>LBH589 ( Panobinostat ) Treatment Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Male female patient age ≥ 18 year old 2 . Ability provide write informed consent obtain prior participation study relate procedure perform 3 . Newly diagnose MF intermediate high risk Lille Scoring System ( Hb &lt; 10g/dL , WBC &lt; 4.0 &gt; 30 X 109/L ; risk group 1=intermediate 2= high ) , symptomatic splenomegaly &gt; 10cm costal margin . 4 . Previously treat MF refractory , intolerant relapse disease 5 . Patients must meet follow laboratory criterion : ANC ≥ 1.0 x 109/L Platelets ≥ 60 x 109/L Calculated CrCl ≥ 45 mL/min ( MDRD Formula ) AST ALT ≤ 2.5 x ULN Serum bilirubin &lt; 1.5 x ULN Albumin &gt; 3.0 g/dl Serum potassium ≥ LLN Total serum calcium [ correct serum albumin ] ionize calcium ≥LLN , Serum magnesium ≥ LLN Serum phosphorus ≥ LLN TSH ≤ ULN free T4 within normal limit . Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . 6 . Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal . 7 . ECOG Performance Status ≤ 2 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer 2 . Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment 3 . Peripheral neuropathy &gt; 1 4 . Impaired cardiac function clinically significant cardiac disease , include one following : Patients congenital long QT syndrome History presence sustain ventricular tachyarrhythmia . ( Patients history atrial arrhythmia eligible discuss Sponsor prior enrollment ) Any history ventricular fibrillation torsade de pointes Bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR ≥ 50 bpm . Screening ECG QTc &gt; 450 msec Right bundle branch block + leave anterior hemiblock ( bifascicular block ) 5 . Patients myocardial infarction unstable angina ≤ 6 month prior start study drug 6 . Other clinically significant heart disease ( e.g. , CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) 7 . Impairment GI function GI disease may significantly alter absorption LBH589 8 . Patients diarrhea &gt; CTCAE grade 1 9 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol 10 . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug 11 . Concomitant use CYP3A4 inhibitor 12 . Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( ever longer ) recover side effect therapy . 13 . Patients receive chemotherapy within 3 week ; radiation therapy &gt; 30 % marrowbearing bone within 3 week prior start study treatment ; yet recover side effect therapy . 14 . Patients active bleeding tendency receive treatment therapeutic dos sodium warfarin ( Coumadin® ) coumadin derivative . Low dos Coumadin® ( e.g . ≤ 2 mg/day ) maintain line patency ( applicable ) allow . 15 . Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy 16 . Women pregnant breastfeed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential must negative serum pregnancy test within 24hrs receive first dose study medication . 17 . Male patient whose sexual partner WOCBP use effective birth control 18 . Patients prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) 19 . Patients know positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require 20 . Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . 21 . Disease associate secondary MF metastatic carcinoma , lymphoma , myelodysplasia , hairy cell leukemia , mast cell disease acute leukemia ( include M7 disease acute panmyelosis MF ) 22 . Presence chromosomal translocation ( 9:22 ) molecular BCR/ABL rearrangement detect RTPCR bone marrow peripheral blood .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>